Abstract
In recent years, growing interest has been focused on the field of cancer prevention. Cancer prevention by chemopreventive agents offers significant promise for reducing the incidence and mortality of cancer. Chemopreventive agents may exert their effects either by blocking or metabolizing carcinogens or by inhibiting tumor cell growth. Another important benefit of chemopreventive agents is their non-toxic nature. Therefore, chemopreventive agents have recently been used for cancer treatment in combination with chemotherapeutics or radiotherapy, uncovering a novel strategy for cancer therapy. This strategy opens a new avenue from cancer prevention to cancer treatment. In vitro and in vivo studies have demonstrated that chemopreventive agents could enhance the antitumor activity of chemotherapeutics, improving the treatment outcome. Growing evidence has shown that chemopreventive agents potentiate the efficacy of chemotherapy and radiotherapy through the regulation of multiple signaling pathways, including Akt, NF-κB, c-Myc, cyclooxygenase-2, apoptosis, and others, suggesting a multitargeted nature of chemopreventive agents. However, further in-depth mechanistic studies, in vivo animal experiments, and clinical trials are needed to investigate the effects of chemopreventive agents in combination treatment of cancer with conventional cancer therapies. More potent natural and synthetic chemopreventive agents are also needed to improve the efficacy of mechanism-based and targeted therapeutic strategies against cancer, which are likely to make a significant impact on saving lives. Here, we have briefly reviewed the role of chemopreventive agents in cancer prevention, but most importantly, we have reviewed how they could be useful for cancer therapy in combination with conventional therapies.
Similar content being viewed by others
Article PDF
References
American Cancer Society. Cancer facts & figures 2007. Atlanta: American Cancer Society; 2007.
Leung WK, Sung JJ . Chemoprevention of gastric cancer. Eur J Gastroenterol Hepatol 2006; 18: 867–71.
Mokbel K . Risk-reducing strategies for breast cancer — a review of recent literature. Int J Fertil Womens Med 2003; 48: 274–7.
McWilliams A, Lam S . New approaches to lung cancer prevention. Curr Oncol Rep 2002; 4: 487–94.
Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 2006; 12: 3661–97.
Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65: 9064–72.
Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH . Inactiva-tion of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005; 65: 6934–42.
Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N . Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kappaB activation levels and in IAP gene expression. Cancer Lett 2005; 224: 53–65.
Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ . Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 2005; 280: 6301–8.
Chan MM, Fong D, Soprano KJ, Holmes WF, Heverling H . Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 2003; 194: 63–70.
Li Y, Kucuk O, Hussain M, Abrams J, Cher ML, Sarkar FH . Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 2006; 66: 4816–25.
Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 2004; 28: e90–e95.
Hwang JT, Ha J, Park OJ . Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 2005; 332: 433–40.
Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, et al. Phenoxodiol — an isoflavone analog — induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003; 22: 2611–20.
Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000; 130: 467S–71S.
Pezzuto JM . Plant-derived anticancer agents. Biochem Pharmacol 1997; 53: 121–33.
Messina MJ, Persky V, Setchell KD, Barnes S . Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113–31.
Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR, Sarkar F, Kucuk O . Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther 2003; 2: 1361–8.
Satoh H, Nishikawa K, Suzuki K, Asano R, Virgona N, Ichikawa T, et al. Genistein, a soy isoflavone, enhances necrotic-like cell death in a breast cancer cell treated with a chemotherapeutic agent. Res Commun Mol Pathol Pharmacol 2003; 113–114: 149–58.
Tanos V, Brzezinski A, Drize O, Strauss N, Peretz T . Synergistic inhibitory effects of genistein and tamoxifen on human dys-plastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol 2002; 102: 188–94.
Lee R, Kim YJ, Lee YJ, Chung HW . The selective effect of genistein on the toxicity of bleomycin in normal lymphocytes and HL-60 cells. Toxicology 2004; 195: 87–95.
Khoshyomn S, Manske GC, Lew SM, Wald SL, Penar PL . Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells. Pediatr Neurosurg 2000; 33: 123–31.
Khoshyomn S, Nathan D, Manske GC, Osler TM, Penar PL . Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells. J Neurooncol 2002; 57: 193–200.
Hillman GG, Forman JD, Kucuk O, Yudelev M, Maughan RL, Rubio J, et al. Genistein potentiates the radiation effect on prostate carcinoma cells. Clin Cancer Res 2001; 7: 382–90.
Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, et al. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 2004; 3: 1271–9.
Yashar CM, Spanos WJ, Taylor DD, Gercel-Taylor C . Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecol Oncol 2005; 99: 199–205.
Akimoto T, Nonaka T, Ishikawa H, Sakurai H, Saitoh JI, Takahashi T, et al. Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways. Int J Radiat Oncol Biol Phys 2001; 50: 195–201.
Constantinou AI, Mehta R, Husband A . Phenoxodiol, a novel isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in female Sprague-Dawley rats. Eur J Cancer 2003; 39: 1012–8.
Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 2006; 106: 599–608.
Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 2004; 14: 567–78.
Choueiri TK, Wesolowski R, Mekhail TM . Phenoxodiol: isoflavone analog with antineoplastic activity. Curr Oncol Rep 2006; 8: 104–7.
Pereira MA, Grubbs CJ, Barnes LH, Li H, Olson GR, Eto I, et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a] anthracene-induced mammary cancer in rats. Carcinogenesis 1996; 17: 1305–11.
Li N, Chen X, Liao J, Yang G, Wang S, Josephson Y, et al. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 2002; 23: 1307–13.
Aggarwal BB, Kumar A, Bharti AC . Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363–98.
Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005; 11: 6738–44.
Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, et al. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2003; 2: 95–103.
Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB . Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-{kappa}B-regulated gene products. Cancer Res 2007; 67: 3853–61.
Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM . Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004; 23: 1599–607.
Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K . Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 2000; 13: 49–54.
Nihal M, Ahmad N, Mukhtar H, Wood GS . Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 2005; 114: 513–21.
Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H, et al. Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 1992; 65: 51–4.
Chisholm K, Bray BJ, Rosengren RJ . Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs 2004; 15: 889–97.
Zhang Q, Wei D, Liu J . In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft. Cancer Lett 2004; 208: 179–86.
Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. Nonsteroidal anti-inflammatory drugs and cyclooxy-genase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146: 376–89.
Sandler AB, Dubinett SM . COX-2 inhibition and lung cancer. Semin Oncol 2004; 31: 45–52.
Ou YC, Yang CR, Cheng CL, Raung SL, Hung YY, Chen CJ . Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur J Pharmacol 2007; in press.
Grosch S, Maier TJ, Schiffmann S, Geisslinger G . Cyclooxy-genase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736–47.
Sorokin A . Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 2004; 10: 647–57.
Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003; 21: 2645–50.
Komaki R, Liao Z, Milas L . Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin Oncol 2004; 31: 47–53.
Shin YK, Park JS, Kim HS, Jun HJ, Kim GE, Suh CO, et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 2005; 65: 9501–9.
Liao Z, Milas L, Komaki R, Stevens C, Cox JD . Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am J Clin Oncol 2003; 26: S85–S91.
Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram N P, Shishodia S, Takada Y . Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004; 24: 2783–840.
Jazirehi AR, Bonavida B . Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2004; 3: 71–84.
Mittal A, Elmets CA, Katiyar SK . Dietary feeding of proantho-cyanidins from grape seeds prevents photocarcinogenesis in SKH-1 hairless mice: relationship to decreased fat and lipid peroxidation. Carcinogenesis 2003; 24: 1379–88.
Martinez C, Vicente V, Yanez J, Alcaraz M, Castells MT, Canteras M, et al. The effect of the flavonoid diosmin, grape seed extract and red wine on the pulmonary metastatic B16F10 melanoma. Histol Histopathol 2005; 20: 1121–9.
Zhang XY, Li WG, Wu YJ, Zheng TZ, Li W, Qu SY, et al. Proanthocyanidin from grape seeds potentiates anti-tumor activity of doxorubicin via immunomodulatory mechanism. Int Immunopharmacol 2005; 5: 1247–57.
Sharma G, Tyagi AK, Singh R P, Chan DC, Agarwal R . Synergis-tic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells. Breast Cancer Res Treat 2004; 85: 1–12.
Cover CM, Hsieh SJ, Cram EJ, Hong C, Riby JE, Bjeldanes LF, et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 1999; 59: 1244–51.
Sarkar FH, Li Y . Indole-3-carbinol and prostate cancer. J Nutr 2004; 134: 3493S–8S.
Morse MA, Amin SG, Hecht SS, Chung FL . Effects of aromatic isothiocyanates on tumorigenicity, O6-methylguanine formation, and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Cancer Res 1989; 49: 2894–7.
Stoner GD, Morrissey DT, Heur YH, Daniel EM, Galati AJ, Wagner SA . Inhibitory effects of phenetyl isothiocyanate on N-nitrosobenzylmethylamine carcinogenesis in the rat esophagus. Cancer Res 1991; 51: 2063–8.
Hecht SS, Kenney PM, Wang M, Trushin N, Upadhyaya P . Effects of phenethyl isothiocyanate and benzyl isothiocyanate, individually and in combination, on lung tumorigenesis induced in A/J mice by benzo[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Lett 2000; 150: 49–56.
Xiao D, Singh SV . Phenethyl isothiocyanate inhibits angiogen-esis in vitro and ex vivo. Cancer Res 2007; 67: 2239–46.
Chaudhuri D, Orsulic S, Ashok BT . Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. Mol Cancer Ther 2007; 6: 334–45.
Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR . Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 2004; 89-90: 533–7.
Kallay E, Bises G, Bajna E, Bieglmayer C, Gerdenitsch W, Steffan I, et al. Colon-specific regulation of vitamin D hydroxylases – a possible approach for tumor prevention. Carcinogenesis 2005; 26: 1581–9.
Nakagawa K, Kawaura A, Kato S, Takeda E, Okano T . 1 alpha, 25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 2005; 26: 429–40.
Siwinska A, Opolski A, Chrobak A, Wietrzyk J, Wojdat E, Kutner A, et al. Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res 2001; 21: 1925–9.
Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R . Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1998; 4: 1345–55.
Schroeder C P, Kadara H, Lotan D, Woo JK, Lee HY, Hong WK, et al. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in pre-malignant human bronchial epithelial cells. Cancer Res 2006; 66: 9762–70.
Aggarwal BB, Shishodia S . Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397–421.
Qin J, Xie LP, Zheng XY, Wang YB, Bai Y, Shen HF, et al. A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochem Biophys Res Commun 2007; 354: 852–7.
Fan XM, Jiang XH, Gu Q, Ching YP, He H, Xia HH, et al. Inhibition of Akt/PKB by a COX-2 inhibitor induces apoptosis in gastric cancer cells. Digestion 2006; 73: 75–83.
Nair AS, Shishodia S, Ahn KS, Kunnumakkara AB, Sethi G, Aggarwal BB . Deguelin, an Akt inhibitor, suppresses Ikappa-Balpha kinase activation leading to suppression of NF-kappaB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion. J Immunol 2006; 177: 5612–22.
Lee HY, Oh SH, Woo JK, Kim W Y, Van Pelt CS, Price RE, et al. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 2005; 97: 1695–9.
McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, et al. Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. Adv Enzyme Regul Mar 21-2007. [Epub ahead of print].
Han Z, Hong L, Wu K, Han S, Shen H, Liu C, et al. Reversal of multidrug resistance of gastric cancer cells by downregulation of Akt1 with Akt1 siRNA. J Exp Clin Cancer Res 2006; 25: 601–6.
Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007; 21: 427–38.
Romashkova JA, Makarov SS . NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86–90.
Liang J, Slingerland JM . Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003; 2: 339–45.
Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJ . Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 1994; 9: 3635–45.
Mateyak MK, Obaya AJ, Sedivy JM . c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999; 19: 4672–83.
Lin JK . Suppression of protein kinase C and nuclear oncogene expression as possible action mechanisms of cancer chemo-prevention by Curcumin. Arch Pharm Res 2004; 27: 683–92.
Wilson AJ, Velcich A, Arango D, Kurland AR, Shenoy SM, Pezo RC, et al. Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res 2002; 62: 6006–10.
Lin JK . Cancer chemoprevention by tea polyphenols through modulating signal transduction pathways. Arch Pharm Res 2002; 25: 561–71.
Tao L, Kramer PM, Wang W, Yang S, Lubet RA, Steele VE, et al. Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. Carcinogenesis 2002; 23: 1447–54.
Park JK, Chung YM, Kang S, Kim JU, Kim YT, Kim HJ, et al. c-Myc exerts a protective function through ornithine decarboxylase against cellular insults. Mol Pharmacol 2002; 62: 1400–8.
Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE . Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 1996; 73: 610–4.
Walker TL, Dass CR, Burton MA . Enhanced in vivo tumour response from combination of carboplatin and low-dose c-myc antisense oligonucleotides. Anticancer Res 2002; 22: 2237–45.
Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 2005; 11: 6075–86.
Karin M . Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431–6.
Greten FR, Karin M . The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 2004; 206: 193–9.
Bharti AC, Donato N, Singh S, Aggarwal BB . Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053–62.
Yang F, Oz HS, Barve S, de Villiers WJ, McClain CJ, Varilek GW . The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 2001; 60: 528–33.
Dell'Eva R, Ambrosini C, Minghelli S, Noonan DM, Albini A, Ferrari N . The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis 2007; 28: 404–13.
Jiang J, Slivova V, Sliva D . Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol 2006; 29: 695–703.
Singh RP, Agarwal R . Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 2006; 45: 436–42.
Davis JN, Kucuk O, Sarkar FH . Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 1999; 35: 167–74.
Singh AV, Franke AA, Blackburn GL, Zhou JR . Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res 2006; 66: 1851–8.
Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH . Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-{kappa}B downstream target genes MMP-9 and u PA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007; 67: 3310–9.
Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M, et al. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 2002; 63: 1709–16.
Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG . Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 2006; 6: 107.
Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D . Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 2005; 44: 51–9.
Hussain T, Gupta S, Adhami VM, Mukhtar H . Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer 2005; 113: 660–9.
Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 2005; 7: 30–9.
Elle N, Irmg T, Greg V, Achi S, Helm S, Chri E, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-{kappa}B. FASEB J 2001; 15: 1622–4.
Raffoul JJ, Banerjee S, Singh-Gupta V, Knoll ZE, Fite A, Zhang H, et al. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 2007; 67: 2141–9.
Chen J, Halls SC, Alfaro JF, Zhou Z, Hu M . Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes. Pharm Res 2004; 21: 2095–104.
Aguero MF, Facchinetti MM, Sheleg Z, Senderowicz AM . Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res 2005; 65: 3364–73.
Constantinou AI, Husband A . Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res 2002; 22: 2581–5.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was funded by grants from the National Cancer Institute (No 5R01CA083695, 5R01CA101870, and 5R01CA108535 awarded to FHS), a subcontract award to FHS from the University of Texas MD Anderson Cancer Center through a Specialized Program of Research Excellence (SPORE) grant (No 5P20-CA101936) on pancreatic cancer awarded to James Abbruzzese, and a grant from the Department of Defense (DOD Prostate Cancer Research Program DAMD17-03-1-0042 awarded to FHS).
Rights and permissions
About this article
Cite this article
Sarkar, F., Li, Yw. Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol Sin 28, 1305–1315 (2007). https://doi.org/10.1111/j.1745-7254.2007.00689.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00689.x
Keywords
This article is cited by
-
Antiproliferative Activity of Whey and Casein Bioactive Peptides on Breast Cancer: An In Vitro and In Silico Study
International Journal of Peptide Research and Therapeutics (2022)
-
Naringin inhibits the invasion and migration of human glioblastoma cell via downregulation of MMP-2 and MMP-9 expression and inactivation of p38 signaling pathway
Tumor Biology (2016)
-
Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo
Journal of Experimental & Clinical Cancer Research (2015)
-
Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1/2
Tumor Biology (2015)
-
Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression
Tumor Biology (2014)